KR20150051051A - Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia - Google Patents
Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia Download PDFInfo
- Publication number
- KR20150051051A KR20150051051A KR1020130132459A KR20130132459A KR20150051051A KR 20150051051 A KR20150051051 A KR 20150051051A KR 1020130132459 A KR1020130132459 A KR 1020130132459A KR 20130132459 A KR20130132459 A KR 20130132459A KR 20150051051 A KR20150051051 A KR 20150051051A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- mushroom
- composition
- alcohol
- carbon atoms
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 30
- 235000016842 Clavicorona pyxidata Nutrition 0.000 title abstract description 5
- 241000212367 Artomyces pyxidatus Species 0.000 title abstract 3
- 230000000694 effects Effects 0.000 claims abstract description 48
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 102000019280 Pancreatic lipases Human genes 0.000 claims abstract description 23
- 108050006759 Pancreatic lipases Proteins 0.000 claims abstract description 23
- 229940116369 pancreatic lipase Drugs 0.000 claims abstract description 23
- 239000012675 alcoholic extract Substances 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 51
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 230000002401 inhibitory effect Effects 0.000 claims description 24
- 150000001840 cholesterol esters Chemical class 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 6
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 240000000249 Morus alba Species 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 241000219823 Medicago Species 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 240000000982 Malva neglecta Species 0.000 claims 1
- 235000000060 Malva neglecta Nutrition 0.000 claims 1
- 235000008708 Morus alba Nutrition 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 108010087173 bile salt-stimulated lipase Proteins 0.000 abstract description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 241001098054 Pollachius pollachius Species 0.000 description 25
- 238000010521 absorption reaction Methods 0.000 description 17
- 238000000605 extraction Methods 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- VSMOENVRRABVKN-UHFFFAOYSA-N oct-1-en-3-ol Chemical compound CCCCCC(O)C=C VSMOENVRRABVKN-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 108090001060 Lipase Proteins 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 240000000643 Alnus japonica Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 244000275339 Clavicorona pyxidata Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 239000001512 FEMA 4601 Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 240000004658 Medicago sativa Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019203 rebaudioside A Nutrition 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000003377 Allium tuberosum Species 0.000 description 1
- 235000005338 Allium tuberosum Nutrition 0.000 description 1
- 241000219496 Alnus Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000014679 Morus rubra var. rubra Nutrition 0.000 description 1
- 235000014677 Morus rubra var. tomentosa Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001516476 Vanda Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004903 negative regulation of intestinal cholesterol absorption Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940087380 vitamin b 12 0.2 mg Drugs 0.000 description 1
- 229940084609 vitamin b 12 0.5 mg Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 좀나무싸리버섯 추출물에 관한 것으로서, 보다 상세하게는 고지혈증의 치료, 예방 등에 유효한 좀나무싸리버섯의 알코올 추출물을 유효 성분으로 하는 고지혈증의 치료 또는 예방용 조성물에 관한 것이다. More particularly, the present invention relates to a composition for treating or preventing hyperlipidemia, which comprises an alcoholic extract of Alaska pollack mushroom effective for the treatment and prevention of hyperlipidemia.
고지혈증은 혈액 속에 지방성분이 높은 상태의 질병을 말한다. 일반적으로 총 콜레스테롤이 240 ㎎/dl을 넘거나 중성지방이 200 ㎎/dl 이상일 때 고지혈증이라 한다. 고지혈증은 콜레스테롤 덩어리가 혈관을 막고 혈액순환을 저해해 고혈압, 심근경색, 뇌졸증 등을 유발하는 주요 원인으로 알려져 있다.Hyperlipidemia refers to a disease of high blood fat content. Generally, when total cholesterol is over 240 ㎎ / dl or triglycerides are over 200 ㎎ / dl, it is called hyperlipidemia. Hyperlipidemia is known to be a major cause of hypertension, myocardial infarction, and stroke due to cholesterol blocks the blood vessels and inhibits blood circulation.
콜레스테롤에 의한 고지혈증의 예방 또는 치료를 위해, 콜레스테롤의 흡수를 저해하는 물질에 대한 연구가 이루어지고 있다. 현재 콜레스테롤 흡수 저해에 의한 고지혈증 치료약물로는 스타틴(statin)계열의 약물이 널리 사용되고 있다. 이 계열의 약은 H㎎-CoA 환원효소 억제제로 콜레스테롤 합성 억제 및 혈중 LDL-콜레스테롤을 저하시키는 효과가 있다. 이 외에도 에제티미브(ezetimibe), 니아신(niacin) 그리고 피브레이트(fibrate) 제제 등이 주로 사용되고 있으나 약물 투여 시 드물게 근육통, 변비 내지는 소화장애 및 간 기능 장애가 발생하는 부작용이 생길 우려가 있다.BACKGROUND ART In order to prevent or treat hyperlipidemia due to cholesterol, studies have been made on substances that inhibit the absorption of cholesterol. Currently, statin drugs are widely used for the treatment of hyperlipidemia due to inhibition of cholesterol absorption. The drug in this series is an inhibitor of Hmg-CoA reductase and has the effect of inhibiting cholesterol synthesis and lowering blood LDL-cholesterol. In addition, ezetimibe, niacin and fibrate preparations are mainly used. However, there is a possibility that side effects such as myalgia, constipation or digestive disorder and hepatic dysfunction are rarely observed when the drug is administered.
PCT/KR2012/10604에서는 젖색손등버섯의 알코올 추출물이 췌장 콜레스테롤 에스터레이즈의 활성을 억제하여 콜레스테롤의 흡수를 저하함으로써 고지혈증의 치료 및 예방용 조성물로 사용될 수 있음이 공개되었다. In PCT / KR2012 / 10604, it has been disclosed that the alcohol extract of Pseudomonas aeruginosa can inhibit the activity of pancreatic cholesterol ester raise and lower the absorption of cholesterol, thereby being used as a composition for treating and preventing hyperlipidemia.
PCT/KR2012/10612에서는 붉은덕다리버섯의 물 추출물이 췌장 콜레스테롤 에스터레이즈의 활성을 억제하여 콜레스테롤의 흡수를 저하함으로써 고지혈증의 치료 및 예방용 조성물로 사용될 수 있음이 공개되었다. In PCT / KR2012 / 10612, it has been disclosed that the water extract of red mulberry can inhibit the activity of pancreatic cholesterol ester raise and lower the absorption of cholesterol, thereby being used as a composition for treating and preventing hyperlipemia.
PCT/KR2012/10550에서는 꽃방패버섯의 알코올 추출물이 췌장 콜레스테롤 에스터레이즈의 활성을 억제하여 콜레스테롤의 흡수를 저하함으로써 고지혈증의 치료 및 예방용 조성물로 사용될 수 있음이 공개되었다. In PCT / KR2012 / 10550, it has been disclosed that the alcohol extract of the flower shield mushroom can inhibit the activity of pancreatic cholesterol ester raise and lower the absorption of cholesterol, thereby being used as a composition for treating and preventing hyperlipidemia.
한편, 중성지방에 의한 고지혈증의 치료 및 예방을 위해, 소화효소에 작용하여 지방의 흡수를 저해하는 작용기전을 가지는 약물들에 대한 연구가 이루어지고 있다. On the other hand, in order to treat and prevent hyperlipidemia due to triglyceride, studies have been made on drugs having a mechanism of action that acts on digestive enzymes and inhibits the absorption of fat.
대표적인 약물로는 XenicalTM(orlistat)가 잘 알려져 있는데, 위장관 지방분해효소(triglyceride lipase, TGL)의 활성부위인 세린과 공유결합을 하여 TGL의 활성을 저해함으로써, 지방이 분해되어 흡수되는 것을 방해한다. Xenical TM (orlistat) is well known as a typical drug. It inhibits the activity of TGL by covalent bonding with serine, which is the active site of triglyceride lipase (TGL), and prevents the fat from being degraded and absorbed .
우승은 등은 “비만 억제를 위한 췌장 리파아제 도메인에 대한 특이 난황항체의 개발” Kor. J. Microbiol. Biotechnol. Vol. 36, No. 4, 299?306 (2008)에서 특이 난황항체를 이용해 췌장 리파아제의 활성을 저해시켜 지방의 흡수를 막는 방법을 제시하고 있다. "Development of specific egg yolk antibodies to the pancreatic lipase domain for obesity inhibition" Kor. J. Microbiol. Biotechnol. Vol. 36, No. 4, 299? 306 (2008) proposes a method of inhibiting the absorption of fat by inhibiting the activity of pancreatic lipase using a specific egg yolk antibody.
PCT/KR2012/10558에서는 노란반달버섯의 알코올 추출물이 췌장 리파아제의 활성을 억제하여 비만 치료 및 예방용 조성물로 사용될 수 있음이 공개되었다. In PCT / KR2012 / 10558, it has been disclosed that the alcohol extract of yellow vanda mushroom can be used as a composition for treating and preventing obesity by inhibiting the activity of pancreatic lipase.
PCT/KR2012/10602에서는 꽃흰목이 버섯의 물 추출물이 췌장 리파아제의 활성을 억제하여 비만 치료 및 예방용 조성물로 사용될 수 있음이 공개되었다.In PCT / KR2012 / 10602, it has been disclosed that water extract of Chrysanthemum morbus Mushroom can be used as a composition for treating and preventing obesity by inhibiting the activity of pancreatic lipase.
한편, PCT/KR2012/10621에서는 아까시버섯의 물 추출물이 췌장 리파아제의 활성과 췌장 콜레스테롤 에스터레이즈의 활성을 억제하며, 지방의 흡수를 저해할 수 있는 것으로 알려졌다. On the other hand, in PCT / KR2012 / 10621, water extract of acacia mushroom suppresses the activity of pancreatic lipase and the activity of raising pancreatic cholesterol ester, and it is known that it can inhibit fat absorption.
그러나 지방과 콜레스테롤의 흡수를 저해하여 고지혈증과 비만을 효과적으로 치료 예방할 수 있는 새로운 버섯 추출물에 대한 요구가 계속되고 있다. However, there is a continuing need for a new mushroom extract which can inhibit the absorption of fat and cholesterol and effectively prevent hyperlipidemia and obesity.
본 발명에서 해결하고자 하는 과제는 생체 내 부작용이 거의 나타나지 않고, 지방과 콜레스테롤의 흡수를 저해할 수 있는 새로운 버섯 추출물을 제공하는 것이다. A problem to be solved by the present invention is to provide a novel mushroom extract which can inhibit the absorption of fat and cholesterol without showing any side effects in vivo.
본 발명에서 해결하고자 하는 다른 과제는 췌장 콜레스테롤 에스터레이즈의 활성과췌장 리파아제의 활성을 저해할 수 있는 새로운 버섯 추출물을 제공하는 것이다. Another object of the present invention is to provide a novel mushroom extract which can inhibit the activity of raising pancreatic cholesterol ester and the activity of pancreatic lipase.
본 발명에서 해결하고자 하는 과제는 지방과 콜레스테롤의 흡수를 저해하여 고지혈증을 치료 또는 예방할 수 있는 조성물을 제공하는 것이다. A problem to be solved by the present invention is to provide a composition capable of inhibiting the absorption of fat and cholesterol and treating or preventing hyperlipidemia.
상기와 같은 목적을 달성하기 위하여, 본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 고지혈증의 치료 또는 예방 조성물을 제공한다.In order to accomplish the above object, the present invention provides a composition for treating or preventing hyperlipidemia comprising an alcohol extract having 1 to 10 carbon atoms in a mushroom.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 고지혈증의 치료 또는 예방용 의약품을 제공한다.The present invention provides a medicament for treating or preventing hyperlipidemia, which comprises an alcohol extract having 1 to 10 carbon atoms in Alfalfa mushroom as an active ingredient.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 동물에 투여하는 단계를 포함하는 고지혈증 치료 또는 예방 방법을 제공한다.The present invention provides a method for treating or preventing hyperlipidemia comprising administering to an animal an alcoholic extract having 1 to 10 carbon atoms in a mushroom.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 고질혈증의 개선 또는 예방용 건강 기능성 식품을 제공한다.The present invention provides a health functional food for improving or preventing hyperlipidemia, which comprises an alcohol extract having 1 to 10 carbon atoms in Alaska pollack mushroom as an active ingredient.
또한, 본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 췌장콜레스테롤 에스터레이즈의 활성 억제용 조성물을 제공한다. The present invention also provides a composition for inhibiting the activity of raising pancreatic cholesterol ester, which comprises an alcohol extract having 1-10 carbon atoms of Alaska pollack as an active ingredient.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 췌장콜레스테롤 에스터레이즈의 활성 억제용 의약품을 제공한다.The present invention provides a medicament for inhibiting the activity of raising pancreatic cholesterol ester, which comprises an alcohol extract having 1 to 10 carbon atoms of Alaska pollack mushroom as an active ingredient.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 동물에 투여하는 단계를 포함하는 췌장콜레스테롤 에스터레이즈의 활성 억제 방법을 제공한다.The present invention provides a method for inhibiting the activity of pancreatic cholesterol esterase, comprising administering to an animal an alcoholic extract having 1 to 10 carbon atoms in a mushroom.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 췌장콜레스테롤 에스터레이즈의 활성 억제용 건강 기능성 식품을 제공한다.The present invention provides a health-functional food for inhibiting the activity of raising pancreatic cholesterol ester comprising an alcohol extract having 1-10 carbon atoms of Alaska pollack as an active ingredient.
또한, 본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 췌장리파아제의 활성 억제용 조성물을 제공한다. Also, the present invention provides a composition for inhibiting the activity of pancreatic lipase comprising an alcohol extract having 1 to 10 carbon atoms in Alaska pollack as an active ingredient.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 췌장리파아제의 활성 억제용 의약품을 제공한다.The present invention provides a medicament for inhibiting the activity of pancreatic lipase comprising an alcohol extract having 1 to 10 carbon atoms in the mushroom of the present invention as an active ingredient.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 동물에 투여하는 단계를 포함하는 췌장리파아제의 활성 억제 방법을 제공한다.The present invention provides a method for inhibiting the activity of pancreatic lipase comprising the step of administering to an animal an alcohol extract having 1 to 10 carbon atoms in a mushroom.
본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 유효성분으로 포함하는 췌장리파아제의 활성 억제용 건강 기능성 식품을 제공한다.The present invention provides a health-functional food for inhibiting the activity of pancreatic lipase comprising an alcohol extract having 1 to 10 carbon atoms of Alaska pollack mushroom as an active ingredient.
또한, 본 발명은 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물은 췌장 리파아제의 활성을 억제하여 지방의 흡수을 억제함으로써, 비만의 예방 및 치료용 조성물로 사용될 수 있다. In addition, the present invention can be used as a composition for preventing and treating obesity by inhibiting the absorption of fat by inhibiting the activity of pancreatic lipase,
본 발명에 있어서, 상기 좀나무싸리버섯(Clavicorona pyxidata(Fr.) Doty)은 민주름목 나무싸리버섯과 나무싸리버섯속에 속하는 버섯으로 여름부터 가을에?썩은 나무에서 발생한다. 산호형으로 분지가 많고 분지끝은 왕관 모양이며, 표고 재배 후 방치된 폐목에서 많이 발생한다. 썩은 나무에서 발생하여 다른 싸리버섯과 쉽게 구별된다. In the present invention,Clavicorona pyxidata(Fr.) Doty) is a mushroom belonging to the genus Cryptococcus From summer to autumn? It occurs in decayed trees. It is coral type with many branches and the end of the branch is crown shaped. It occurs in rotten wood and is easily distinguishable from other mushrooms.
본 발명에 있어서, 상기 좀나무싸리버섯의 추출물, 특히 좀나무싸리버섯의 알코올 추출물은 췌장콜레스테롤 에스터레이즈의 활성을 저하시키고, 위장관 지방분해효소(triglyceride lipase, TGL)인 췌장리파아제의 활성을 효과적으로 저해하여, 고지혈증을 치료 또는 예방하는 약물을 대체할 수 있다. In the present invention, the extract of Alnus japonicus, especially Alcoholic extract of Alnus japonica, lowers the activity of pancreatic cholesterol ester raise and effectively inhibits the activity of triglyceride lipase (TGL), pancreatic lipase To replace drugs that treat or prevent hyperlipidemia.
본 발명에 있어서, 상기 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물은 탄소수 1 내지 5의 저가 알코올을 추출 용매로 하여 추출된 것일 수 있다. 좀나무싸리버섯을 탄소수 1 내지 5의 저가 알코올로 추출하는 경우, 뛰어난 체내 지방의 소화 및 흡수 저해 효과를 나타낸다. In the present invention, the alcohol extract of Cryptomeria japonica having 1 to 10 carbon atoms may be one obtained by extracting low-valent alcohol having 1 to 5 carbon atoms as an extraction solvent. When extracting low-mushroom with low-carbon alcohol having 1 to 5 carbon atoms, it exhibits excellent digestion and absorption inhibition effect of the body fat.
특히, 이와 같은 알코올 추출 용매로는 바람직하게는 탄소수 1 내지 5의 저가 알코올, 더욱 바람직하게는 에탄올, 가장 바람직하게는 90 내지 99.99 %(v/v)의 에탄올을 사용할 수 있다. Particularly, as such an alcohol extracting solvent, a lower alcohol having 1 to 5 carbon atoms, more preferably ethanol, and most preferably 90 to 99.99% (v / v) ethanol can be used.
본 발명에서 버섯의 무게 또는 중량은 다른 언급이 없는 한, 건조된 버섯의 무게 또는 중량을 언급하는 것으로 이해된다. In the present invention, the weight or weight of the mushroom is understood to refer to the weight or weight of the dried mushroom unless otherwise noted.
한편, 상기와 같은 좀나무싸리버섯의 알코올 추출물은 통상의 식물 추출물의 제조 방법에 따라 제조된 것일 수 있다. 바람직하게는 상기 좀나무싸리버섯을 건조 분쇄한 후에 잔사를 제거한 다음, 탄소수 1 내지 10의 알코올 100 ㎖당 상기 분쇄물 0.1 내지 20g을 첨가하여, 더욱 바람직하게는 추출 용매 100 ㎖당 분쇄물 1 내지 5 g을 첨가하여, 추출할 수 있다. 좀나무싸리버섯 분쇄물의 함량이 추출 용매 대비하여 지나치게 적은 경우, 좀나무싸리버섯의 효과 발휘가 충분하지 않아 바람직하기 않고, 추출 용매의 양 대비 지나치게 많은 경우 함량 증가에 따른 효과의 증대는 크지 않은 반면 생산비용이 증가하므로 생산성 측면에서 바람직하지 않다.On the other hand, the alcoholic extract of the above-mentioned mushroom can be produced according to a conventional method for producing a plant extract. Preferably, after removing the residues after drying and crushing the bark mushroom, 0.1 to 20 g of the pulverized product is added to 100 ml of the alcohol having 1 to 10 carbon atoms, more preferably, 1 to 20 g of the pulverized product per 100 ml of the extraction solvent, 5 g may be added to the solution. When the content of the crushed mushroom is too small compared to the extraction solvent, the effect of the mushroom is not sufficient, and when the amount of the crushed mushroom is excessively large relative to the amount of the extraction solvent, the effect of the increase in the content is not great It is not preferable from the viewpoint of productivity because the production cost is increased.
이때, 추출 조건은 구성의 한정은 없으나, 바람직하게 좀나무싸리버섯을 추출 용매인 탄소수 1 내지 10의 알코올과 혼합한 후, 20 내지 60 ℃의 온도에서 12 내지 36 시간 동안, 더욱 바람직하게는 30 내지 40 ℃의 온도에서 20 내지 24 시간 동안 추출할 수 있다.In this case, the extraction conditions are not limited, but preferably, the mushroom is mixed with an alcohol having 1 to 10 carbon atoms, which is an extraction solvent, at a temperature of 20 to 60 ° C for 12 to 36 hours, more preferably 30 To 40 < 0 > C for 20 to 24 hours.
지나치게 낮은 온도조건에서 추출하는 경우, 유효성분의 추출을 위해서 긴 시간이 요구되며, 지나치게 높은 온도 건에서 추출하는 경우, 활성이 떨어질 수 있어 바람직하지 않다.Extraction at an excessively low temperature condition requires a long time for extracting an active ingredient, and extraction at an excessively high temperature may deteriorate the activity, which is undesirable.
그리고, 추출 시간이 지나치게 짧게 하는 경우, 추출되는 유효성분의 농도가 낮고, 지나치게 긴 시간 동안 추출하는 경우, 추출 시간의 증가에 따른 추출 유효성분의 농도 증가가 미미하여 생산성 측면에서 바람직하지 않다.When the extraction time is too short, the concentration of the effective component to be extracted is low, and when the extraction is performed for an excessively long time, the concentration of the extraction effective ingredient increases with the increase of the extraction time.
그리고, 상기와 같은 방법으로 추출한 좀나무싸리버섯의 알코올 추출액은 여과포 등으로 여과한 후, 여액을 원심분리시켜 침전물을 제거시킨 다음, 감압 농축 또는 농축 한후, 동결 건조할 수 있다.Then, the alcohol extract of the mushroom extract obtained by the above method is filtered through a filter cloth, etc., and the filtrate is centrifuged to remove the precipitate, followed by concentration under reduced pressure or concentration, followed by lyophilization.
한편, 상술한 구현예의 고지혈증과 비만의 치료 또는 예방 조성물 중 유효성분인 좀나무싸리버섯의 알코올 추출물의 함량은 한정은 없으나, 바람직하게는 0.001 내지 50 중량%일 수 있다. 유효성분인 좀나무싸리버섯의 알코올 추출물의 함량이 0.001 중량% 미만인 경우에는, 체내 지방의 소화 흡수 및 저해 효과가 미미하며, 50 중량%를 초과하는 경우에는 함량 증가에 따른 저해활성 증가 효과가 미미하여, 경제적이지 못하다. 더욱 바람직하게는 조성물 내에 좀나무싸리버섯의 알코올 추출물의 함량은 0.01 내지 50 중량%, 가장 바람직하게는 0.1 내지 30 중량%일 수 있다.On the other hand, the content of the alcoholic extract of mushroom mushroom, which is an active ingredient of the above-described embodiment of the composition for treating or preventing obesity and hyperlipidemia, is not limited, but may be preferably 0.001 to 50% by weight. When the content of the alcoholic extract of the mushroom is less than 0.001% by weight, digestion and absorption of the fat in the body are insignificant. When the content is more than 50% by weight, the effect of increasing the inhibitory activity is insignificant It is not economical. More preferably, the content of the alcoholic extract of Alaska pollack may be 0.01 to 50% by weight, and most preferably 0.1 to 30% by weight.
본 발명은 구현예에 따라 상기 조성물에 포함된 좀나무싸리버섯의 알코올 추출물을 유효성분으로 포함하는 고지혈증이나 비만의 치료 또는 예방용 의약품을 제공한다. 이와 같은 좀나무싸리버섯의 알코올 추출물을 유효성분으로 포함하는 의약품은 그 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.The present invention provides a medicament for the treatment or prevention of hyperlipidemia or obesity, which comprises an alcoholic extract of Alaska pollack mushroom contained in the above composition as an active ingredient. The medicinal product containing the alcohol extract of Alaska pollack as an active ingredient may further contain suitable carriers, excipients and diluents conventionally used in the production thereof.
본 발명의 좀나무싸리버섯의 알코올 추출물을 유효성분으로 포함하는 의약품에 포함될 수 있는 담체, 부형제 및 희석제로는 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Examples of carriers, excipients, and diluents that can be included in the medicament containing the alcohol extract of the present invention as an active ingredient include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, , Alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil have.
본 발명의 좀나무싸리버섯의 알코올 추출물을 유효성분으로 포함하는 의약품은 각각 통상의 방법에 따라 산제, 과립제, 정제, 현탁제, 에멀젼, 시럽 등의 경구형 제형물로 사용될 수 있다.The medicinal product containing the alcohol extract of Alaska pollack mushroom of the present invention as an active ingredient can be used as oral formulations such as powders, granules, tablets, suspensions, emulsions and syrups according to a conventional method.
상기 경구형 제형물은 경구 투여를 위한 고형제제와 액상제제를 포함하는 의미이며, 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함될 수 있으며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.The oral formulations are meant to include solid and liquid formulations for oral administration and solid formulations for oral administration may include tablets, pills, powders, granules, capsules and the like, For example, starch, calcium carbonate, sucrose or lactose, gelatin and the like in combination with at least one excipient. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, have.
본 발명의 좀나무싸리버섯의 알코올 추출물을 함유하는 조성물의 바람직한 투여량은 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 바람직하게는 본 발명의 좀나무싸리버섯의 알코올 추출물을 유효성분으로 함유하는 의약품은 좀나무싸리버섯의 알코올 추출물의 양을 기준으로 1일 0.0001 내지 100 ㎎/kg으로, 보다 효과적이기 위해서는 0.01 내지 10 ㎎/kg으로 투여하는 것이 좋다. 투여는 하루에 한 번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량과 투여횟수는 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the composition containing the alcoholic extract of Alaska pollack mushroom of the present invention varies depending on the condition and body weight, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. Preferably, the medicinal product containing the alcohol extract of the present invention as an active ingredient is 0.0001 to 100 mg / kg per day on the basis of the amount of the alcohol extract of Alaska pollack mushroom, and more preferably 0.01 to 10 mg / Mg / kg < / RTI > The administration may be carried out once a day or divided into several doses. The dose and the number of administrations do not limit the scope of the present invention in any aspect.
본 발명의 다른 구현예에 따라, 좀나무싸리버섯의 알코올 추출물을 유효성분으로 포함하는 고지혈증 또는 비만의 개선 또는 예방용 건강 기능성 식품을 제공한다. 여기서 “건강 기능성 식품”이라 함은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미한다.According to another embodiment of the present invention, there is provided a health functional food for improving or preventing hyperlipidemia or obesity, which comprises an alcohol extract of Alaska pollack as an active ingredient. Herein, the term " health functional food " means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be directly eaten through a certain processing step.
본 발명의 좀나무싸리버섯의 알코올 추출물을 첨가할 수 있는 건강 기능성 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영·유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실·채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면 스프 등)을 포함하나 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조 방법으로 제조될 수 있다.Examples of the health functional food to which the alcohol extract of Alaska pollack mushroom of the present invention can be added include various foods, beverages, gums, tea, vitamin complex, and the like. In addition, in the present invention, the food may contain special nutritional foods (eg, crude oil, infant formula, etc.), meat products, fish products, tofu, mackerel, noodles (eg, (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods (For example, fruits and vegetables, beverages, fermented beverages, etc.), natural seasonings (eg, ramen soup, etc.). The food, beverage or food additive may be prepared by a conventional production method.
본 명세서에서, 기능성 식품이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다. 상기 기능성 식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.In the present specification, the functional food refers to a food group which is imparted with added value to function and express the function of the food by using physical, biochemical, biotechnological techniques, etc., Means a food which is processed and designed so that the body control function related to restoration and the like is sufficiently expressed to the living body. The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.
본 명세서에서, 음료란 갈증을 해소하거나 맛을 즐기기 위하여 마시는 것의 총칭을 의미하며 기능성 음료를 포함하는 의도이다. 상기 음료는 지시된 비율로 필수 성분으로서 상기 좀나무싸리버섯의 알코올 추출물을 유효성분으로 포함하는 것 외에 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기의 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 5 내지 12 g일 수 있다. 그밖에 본 발명의 조성물은 천연과일주스, 과일주스음료, 야채음료의 제조를 위한 과육을 추가로 함유할 수 있다.In the present specification, beverage means a generic term for drinking or enjoying a taste and is intended to include a functional beverage. The above-mentioned beverage is not particularly limited as long as it contains an alcoholic extract of the bark mushroom as an active ingredient as an essential ingredient at the indicated ratio, and may be added with various flavors or natural carbohydrates as an additional ingredient ≪ / RTI > Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and Xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate may be generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention. In addition, the composition of the present invention may be used for natural fruit juice, fruit juice drink, And may further contain flesh for manufacture.
상기 외에 본 발명의 건강 기능성 식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분을 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하지 않지만, 본 발명의 좀나무싸리버섯의 알코올 추출물 100 중량부당 0 내지 20 중량부 범위에서 선택될 수 있다.In addition to the above, the health functional food of the present invention may contain various kinds of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, And salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. These components can be used independently or in combination. The proportion of such additives is not critical, but may be selected in the range of 0 to 20 parts by weight per 100 parts by weight of the alcohol extract of the present invention.
본 명세서에서 기능성 음료란 음료에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 음료의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 음료 군이나 음료 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 음료를 의미한다.In the present specification, functional beverages are used to control the bio-defense rhythm of the beverage group or beverage composition to which the added value is imparted so that the function of the beverage functions for a specific purpose by using physical, biochemical, biotechnological techniques, Means a beverage which has been designed so that the body control function related to restoration and the like is sufficiently expressed in the living body.
상기 기능성음료는 지시된 비율로 필수 성분으로서 본 발명의 좀나무싸리버섯의 알코올 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 5 내지 12 g이다.The functional beverage is not particularly limited to the other components other than the alcoholic extract of the present invention as an essential ingredient in the indicated ratios and may contain various flavors or natural carbohydrates as an additional ingredient can do. Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and xylitol , Sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention.
또한, 고지혈증 또는 비만의 개선 또는 예방을 목적으로 하는 건강 기능성 식품에 있어서, 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 포함할 수 있으며, 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 포함할 수 있다.In addition, in a health functional food for the purpose of improving or preventing hyperlipidemia or obesity, the amount of the extract may be 0.01 to 15% by weight of the total food, and the beverage composition may contain 0.02 to 5 g , Preferably 0.3 to 1 g.
한편, 본 발명은 또 다른 구현예에 따라 상기와 같은 좀나무싸리버섯의 알코올 추출물을 제조하는 방법을 제공한다.According to another embodiment of the present invention, there is provided a method for preparing an alcoholic extract of Alaska pollack as described above.
본 발명의 일 구현예에 따른 좀나무싸리버섯의 알코올 추출물의 제조 방법은 좀나무싸리버섯을 준비하는 단계와, 상기 좀나무싸리버섯을 탄소수 1 내지 10의 알코올과 혼합하는 단계와, 상기 혼합물을 20 내지 60 ℃의 온도에서 12 내지 36 시간 동안 추출하는 단계를 포함한다.The method for preparing an alcoholic extract of Alaska pollack according to an embodiment of the present invention includes the steps of preparing Alaskan mushroom, mixing the Alaskan mushroom with an alcohol having 1 to 10 carbon atoms, At a temperature of 20 to 60 DEG C for 12 to 36 hours.
한편, 상술한 구현예에 따른 좀나무싸리버섯의 탄소수 1 내지 10의 알코올 추출물을 제조하는 방법에 있어서, 상기 알코올은 탄소수 1 내지 5의 알코올, 더욱 바람직하게는 에탄올, 가장 바람직하게는 90 내지 99.9 %(v/v)의 에탄올일 수 있다. 이와 같은 추출 용매로 추출하는 경우, 추출된 추출물의 콜레스테롤이 소화 및 흡수 저해 효과와, 지방의 소화 및 흡수 저해 효과와 더불어 소화관으로부터 혈액으로의 콜레스테롤과 지방 흡수량 감소 효능이 뚜렷하게 나타나는 것을 알 수 있었다. 구체적인 추출 시간, 추출 온도 및 좀나무싸리버섯과 추출 용매의 혼합 비율 등은 상술한 것에 갈음한다.Meanwhile, in the method for producing an alcoholic extract having 1 to 10 carbon atoms in the mushroom of the present invention, the alcohol is an alcohol having 1 to 5 carbon atoms, more preferably ethanol, most preferably 90 to 99.9 % (v / v) ethanol. When extracted with such an extraction solvent, it was found that cholesterol from the digestive tract and the effect of reducing the amount of fat absorption from the digestive tract were remarkably exhibited in addition to the effect of inhibiting digestion and absorption of cholesterol and inhibiting digestion and absorption of fat in the extracted extract. The specific extraction time, the extraction temperature, and the mixing ratio of the bark mushroom and the extraction solvent are different from those described above.
본 발명의 좀나무싸리버섯의 알코올 추출물을 유효성분으로 포함하는 조성물은 췌장콜레스테로 에스터레이즈 및 췌장리파아제의 활성을 저해하여, 콜레스테롤, 지방, 또는 양자의 소화 및 흡수를 저해하여 고지혈증의 치료 또는 예방 용도와 비만의 치료 또는 예방 용도로 유용하게 사용될 수 있다.The composition of the present invention comprising an alcohol extract of Alaska pollack mushroom as an active ingredient inhibits the activity of pancreatic cholesterol esterase and pancreatic lipase to inhibit digestion and absorption of cholesterol, fat, or both to treat or prevent hyperlipidemia Can be usefully used for the prophylactic use and the therapeutic or prophylactic use of obesity.
도 1은 좀나무싸리버섯의 알코올 추출물의 췌장 콜레스테롤 에스터레이즈의 활성저해효능을 대조구와 비교하여 나타낸 그래프이다.
도 2는 좀나무싸리버섯의 알코올 추출물의 췌장리파아제의 활성저해효능을 대조구와 비교하여 나타낸 그래프이다. FIG. 1 is a graph showing the inhibitory activity of pancreatic cholesterol esterase in the alcohol extract of Alaska pollack mushroom compared with the control.
FIG. 2 is a graph showing the inhibitory activity of pancreatic lipase in the alcohol extract of Alnus japonica against the control.
이하, 본 발명의 구체적인 실시예를 통해서 발명의 구성 및 효과를 보다 상세하게 설명하기로 한다. 그러나, 하기의 실시예는 발명을 보다 명확하게 이해시키기 위한 것일 뿐이며, 발명의 권리범위가 하기 실시예에 한정되는 것은 아니다. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the structure and effects of the present invention will be described in detail with reference to specific embodiments of the present invention. It should be understood, however, that the following examples are provided for a better understanding of the invention and are not to be construed as limiting the scope of the invention.
이하, 본 발명을 실시예를 통해 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to examples.
실시예: 좀나무싸리버섯 알코올 추출물 준비EXAMPLES: Preparation of Alaska pollack mushroom alcohol extract
경상북도 산림환경연구원에서 제공받은 건조된 좀나무싸리버섯(Clavicorona pyxidata.) 분말 2 g당, 추출 용매로 알코올 50 ㎖를 혼합한 후, 37 ℃에서 24 시간 동안 진탕배양기에 두어 추출하였다. 진탕배양기의 상등액을 2500 rpm으로 10 분 동안 원심분리한 후 좀나무싸리버섯 알코올 추출물을 수집하였으며, -20℃에서 보관하였다.
Fifty milliliters of alcohol was extracted with 2 g of dried Clavicorona pyxidata powder obtained from Gyeongsangbuk - do Research Institute for Forest Environment, and the mixture was extracted with shaking incubator at 37 ℃ for 24 hours. The supernatant of the shaking incubator was centrifuged at 2500 rpm for 10 minutes, then the extract of Alaska pollack mushroom alcohol was collected and stored at -20 ° C.
실험예: Experimental Example:
1. 좀나무싸리버섯 알코올 추출물에 의한 췌장 콜레스테롤 에스터레이즈 활성 측정 및 결과1. Measurement and Results of Pancreatic Cholesterol Ester Raise Activity by Alcohol Extract
췌장 콜레스테롤 에스터레이즈는 acyl chain을 가지는 기질들을 비 특이적으로 인식하여 acyl chain을 분리하는 역할을 한다. 실시예의 좀나무싸리버섯 알코올 추출물에 의한 췌장 콜레스테롤 에스터레이즈 활성을 측정하기 위하여, 효소로 시그마 케미칼에서 제조된 포오신 판크리틱 콜레스테롤 에스터레이즈를 사용하였다. 췌장 콜레스테롤 에스터레이즈가 chromo-genic substrate (p-nirophenylbutyrate)을 분해하는 성질을 이용하여 발색반응을 통해 효소의 활성변화를 확인하였다. 효소의 활성저해효과는 Microplate reader를 이용하여 405 nm의 흡광도의 변화를 통해 측정하고, 추출물 비처리 그룹의 405 nm 흡광도를 베이스로 하여 계산하여 %로 나타내었다.Pancreatic cholesterol esterase plays a role in recognizing acyl chain-bearing substrates as non-specific and isolating acyl chains. In order to measure the activity of pancreatic cholesterol ester raising by the mushroom alcohol extract of mushroom of the Examples, a poison pancreatic cholesterol ester raise made in Sigma chemical was used as an enzyme. Pancreatic cholesterol esterase cleaved the chromo-genic substrate (p-nirophenylbutyrate), and the activity of the enzyme was confirmed by color reaction. The inhibitory effect of the enzyme was measured by the change of absorbance at 405 nm using a microplate reader and expressed as% based on the absorbance at 405 nm of the extract-untreated group.
실시예의 좀나무싸리버섯 알코올 추출물에 의해 효소의 활성이 어떻게 달라지는지 측정하였고, 그 결과 좀나무싸리버섯 알코올 추출물이 췌장 콜레스테롤 에스터레이즈 활성이 저하시키는 것을 확인하였다. 결과는 도 1에 간단하게 나타내었다.The activity of the enzyme was determined by the extract of Alaska pollack mushroom alcohol of the present invention. As a result, it was confirmed that the extract of Alaska pollack mushroom alcohol lowered the pancreatic cholesterol ester raising activity. The results are briefly shown in Fig.
2. 좀나무싸리버섯 알코올 추출물에 의한 췌장 리파아제 활성 측정 및 결과2. Measurement and Results of Pancreatic Lipase Activity by Alcohol Extract
췌장 리파아제는 acyl chain을 가지는 기질들을 비 특이적으로 인식하여 acyl chain을 분리하는 역할을 한다. 좀나무싸리버섯 알코올 추출물에 의한 췌장 리파아제 활성을 측정하기 위하여, 효소로 시그마 케미칼에서 제조된 포오신 판크리틱 췌장 리파아제 타입 2(porcine pancreatic lipase; Type Ⅱ, Sigma chemical)를 사용하였다. 췌장 리파아제가 chromo-genic substrate (p-nirophenylbutyrate)을 분해하는 성질을 이용하여 발색반응을 통해 효소의 활성 변화를 확인하였다. 효소의 활성저해효과는 Microplate reader를 이용하여 405 nm의 흡광도의 변화를 통해 측정하고, 좀나무싸리버섯 알코올 추출물 비처리 그룹의 405 nm 흡광도를 베이스로 하여 계산하여 %로 나타내었다. 좀나무싸리버섯 알코올 추출물에 의해 효소의 활성이 어떻게 달라지는지 측정하였고, 그 결과 실시예의 좀나무싸리버섯 알코올 추출물이 췌장 리파아제 활성이 저하시키는 것을 확인하였다. 결과를 도 2에 간단히 나타내었다.
Pancreatic lipase plays a role in recognizing acyl chain-bearing substrates nonspecifically and isolating acyl chains. Porcine pancreatic lipase (Type II, Sigma chemical), an enzyme produced by Sigma Chemical, was used to measure the activity of pancreatic lipase by alfalfa extract. Using pancreatic lipase's ability to decompose chromo-genic substrate (p-nirophenylbutyrate), the activity of the enzyme was confirmed through color development. The inhibitory effect of the enzyme was measured by the change of absorbance at 405 nm using a microplate reader and calculated as% based on the absorbance at 405 nm of the untreated group of Allium tuberosum L. extract. The activity of the enzyme was determined by the extract of Alaska pollack mushroom alcohol. As a result, it was confirmed that the extract of Alaska pollack mushroom alcohol decreased the activity of pancreatic lipase. The results are briefly shown in Fig.
제조예 : 좀나무싸리버섯 알코올 추출물을 이용한 제제Preparation Example: Preparation using a mushroom alcohol extract
제조예 1. 산제의 제조Production Example 1. Preparation of powder
좀나무싸리버섯 알코올 추출물 분말 20 ㎎, 유당 100 ㎎, 탈크 10 ㎎.20 mg of powdery mushroom alcohol extract, 100 mg of lactose, 10 mg of talc.
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above ingredients were mixed and filled in an airtight container to prepare powders.
제조예 2. 정제의 제조Production Example 2. Preparation of tablets
좀나무싸리버섯 알코올 추출물 10 ㎎, 옥수수전분 100 ㎎, 유당 100 ㎎, 스테아린산 마그네슘 2 ㎎.100 mg of corn starch, 100 mg of lactose, 2 mg of magnesium stearate.
상기의 성분들을 혼합한 후 통상의 정제의 제조 방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to the usual preparation method of tablets.
제조예 3. 캡슐제의 제조Production Example 3. Preparation of capsules
좀나무싸리버섯 알코올 추출물 분말 10 ㎎, 결정성 셀룰로오스 3 ㎎, 락토오스 14.8 ㎎, 마그네슘 스테아레이트 0.2 ㎎.10 mg of powdered mushroom alcohol extract, 3 mg of crystalline cellulose, 14.8 mg of lactose, and 0.2 mg of magnesium stearate.
통상의 캡슐제 제조 방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.The above components were mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제조예 4. 액제의 제조Production Example 4. Production of liquid agent
좀나무싸리버섯 알코올 추출물 분말 20 ㎎, 이성화당 10 g, 만니톨 5 g, 정제수 적량.20 mg of powdery mushroom alcohol extract, 10 g of isomerized sugar, 5 g of mannitol, and purified water.
통상의 액제의 제조 방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조하였다.Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.
제조예 5. 건강식품의 제조Production Example 5. Production of Health Food
좀나무싸리버섯 알코올 추출물 분말 1000 ㎎, 비타민 혼합물 적량, 비타민 A 아세테이트 70 ㎍, 비타민 E 1.0 ㎎, 비타민 B1 0.13 ㎎, 비타민 B2 0.15 ㎎, 비타민 B6 0.5 ㎎, 비타민 B12 0.2 ㎍, 비타민 C 10 ㎎, 비오틴 10 ㎍, 니코틴산아미드 1.7 ㎎, 엽산 50 ㎍, 판토텐산 칼슘 0.5 ㎎, 무기질 혼합물 적량, 황산제1철 1.75 ㎎, 산화아연 0.82 ㎎, 탄산마그네슘 25.3 ㎎, 제1인산칼륨 15 ㎎, 제2인산칼슘 55 ㎎, 구연산칼륨 90 ㎎, 탄산칼슘 100㎎, 염화마그네슘 24.8 ㎎.Vitamin B acetate 0.2 mg, Vitamin C 10 mg, Vitamin C 0.1 mg, Vitamin B 0.13 mg, Vitamin B 0.15 mg, Vitamin B12 0.5 mg, Vitamin B12 0.2 mg, Vitamin A acetate 70 mg, Vitamin A acetate 70 mg, 10 ㎍ of biotin, 1.7 ㎎ of nicotinic acid amide, 50 ㎍ of folate, 0.5 mg of calcium pantothenate, 1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of potassium phosphate, 55 mg of potassium citrate, 90 mg of potassium citrate, 100 mg of calcium carbonate, and 24.8 mg of magnesium chloride.
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조 방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130132459A KR101598668B1 (en) | 2013-11-01 | 2013-11-01 | Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130132459A KR101598668B1 (en) | 2013-11-01 | 2013-11-01 | Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150051051A true KR20150051051A (en) | 2015-05-11 |
KR101598668B1 KR101598668B1 (en) | 2016-03-03 |
Family
ID=53388657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130132459A KR101598668B1 (en) | 2013-11-01 | 2013-11-01 | Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101598668B1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060116280A (en) * | 2005-05-09 | 2006-11-15 | 한영환 | Composition and extracts of clavicorona pyxidata for curing alzheimer's disesase |
KR20130065086A (en) * | 2011-12-09 | 2013-06-19 | 포항공과대학교 산학협력단 | Composition comprsing alcohol extracts from albatrellus dispansus for treating or preventing hyperlipidemia |
KR20130065127A (en) * | 2011-12-09 | 2013-06-19 | 포항공과대학교 산학협력단 | Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia |
-
2013
- 2013-11-01 KR KR1020130132459A patent/KR101598668B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060116280A (en) * | 2005-05-09 | 2006-11-15 | 한영환 | Composition and extracts of clavicorona pyxidata for curing alzheimer's disesase |
KR20130065086A (en) * | 2011-12-09 | 2013-06-19 | 포항공과대학교 산학협력단 | Composition comprsing alcohol extracts from albatrellus dispansus for treating or preventing hyperlipidemia |
KR20130065127A (en) * | 2011-12-09 | 2013-06-19 | 포항공과대학교 산학협력단 | Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia |
Also Published As
Publication number | Publication date |
---|---|
KR101598668B1 (en) | 2016-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101490786B1 (en) | Composition comprising water extracts from fomitella fraxinea (fr.) imaz. for treating or preventing obesity | |
KR101565964B1 (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
KR101490781B1 (en) | Composition comprsing alcohol extracts from albatrellus dispansus for treating or preventing hyperlipidemia | |
KR101722297B1 (en) | ISOLATION OF SINGLE COMPOUND FROM Albatrellus fletti ITS APPLICATION IN TREATING AND PREVENTING OBESITY | |
KR101691256B1 (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Oligoporus stipticus, FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR101490794B1 (en) | Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia | |
KR101594649B1 (en) | Composition comprising alcohol extracts from ramaria stricta for treating or preventing hyperlipidemia | |
KR101783085B1 (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Russula eccentrica FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR101598668B1 (en) | Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia | |
KR101706516B1 (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM Lactarius Volemus FOR TREATING OR PREVENTING OBESITY | |
KR101773221B1 (en) | Composition comprising alcohol extracts from russula japonica for treating or preventing hyperlipidemia | |
KR101634200B1 (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Bjerkandera adusta. FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR101569254B1 (en) | composition comprising water extracts from oudemansiella platyphylla for treating or preventing hyperlipidemia | |
KR101626191B1 (en) | Composition comprising water extracts from suillus bovinus for treating or preventing hyperlipidemia | |
KR101706431B1 (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM Lactarius Volemus FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR101490800B1 (en) | Composition comprising water extracts from laetiporus sulphureus var. miniatus (jungh.) imaz. for treating or preventing hyperlipidemia | |
KR20170039635A (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM pleurotus cornucopiae FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR20170116597A (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM pleurotus cornucopiae(paulet) Rolland FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR101625280B1 (en) | COMPOSITION COMPRSING ALCOHOL EXRACTS FROM Albatrellus fletti FOR TREATING OR PREVENTING OBESITY | |
KR20160104590A (en) | Composition comprising alcohol extracts from russula japonica for treating or preventing hyperlipidemia | |
KR20160075915A (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM pleurotus cornucopiae FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR20130065117A (en) | Composition comprising water extracts from tremella foliacea fr. for treating or preventing obesity | |
KR20150048698A (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
KR20160075902A (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Fomitopsis sp. FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR20160075906A (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Tranmetes hirsuta FOR TREATING OR PREVENTING HYPERLIPIDEMIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20190129 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20200120 Year of fee payment: 5 |